Biogen Inc. (1BIIB)
MTA
Closed
Oct 2, 2026
Day's Range
196.6252 wk Range
121.50Overview - 1BIIB - Biogen Inc.
Key Statistics
Valuation
Enterprise Value
31.77B
P/E (Trailing)
‪40.09‬
PEG Ratio
‪-0.47‬
Price / Sales (TTM)
‪2.90‬
Price / Book
‪1.77‬
EV / EBITDA
‪10.78‬
Profitability
Gross Margin
‪71.60%‬
Profit Margin
‪8.32%‬
Operating Margin
‪25.05%‬
Return on Assets
‪5.20%‬
Return on Equity
‪4.57%‬
Ownership
Shares Outstanding
147.70M
Float
147.21M
Held by Insiders
‪0.18%‬
Held by Institutions
‪99.49%‬
Price stats
Beta
‪0.17‬
50-Day Avg
‪184.36‬
200-Day Avg
‪167.21‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - 1BIIB - Biogen Inc.
Peers - 1BIIB - Biogen Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on MTA.
- 1BIIBMTABiogen Inc.23.34BMarket Cap+40.79%52-week change40.09P/E (Trailing)‪8.32%‬Profit Margin
- 1LLYMTAEli Lilly and Company853.56BMarket Cap+39.59%52-week change39.07P/E (Trailing)‪33.52%‬Profit Margin
- 1JNJMTAJohnson & Johnson428.46BMarket Cap+35.10%52-week change31.33P/E (Trailing)‪21.48%‬Profit Margin
- 1ABBVMTAAbbVie Inc.344.57BMarket Cap+18.25%52-week change74.58P/E (Trailing)‪9.80%‬Profit Margin
- 1ROMTARoche Holding AG294.63BMarket Cap+26.64%52-week change24.41P/E (Trailing)‪19.60%‬Profit Margin
- 1MRKXMTAMerck & Co., Inc.240.41BMarket Cap+48.40%52-week change117.34P/E (Trailing)‪4.76%‬Profit Margin
- 1NOVNMTANovartis AG Registered Shares238.75BMarket Cap+17.17%52-week change21.78P/E (Trailing)‪22.50%‬Profit Margin
Profile Summary - 1BIIB - Biogen Inc.
About
Biogen Inc. is a biotechnology company focused on discovering, developing, and delivering therapies for serious neurological, neurodegenerative, and rare diseases. Biogen’s current portfolio includes treatments for multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis, and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
